felin
infecti
periton
viru
fipv
caus
lethal
diseas
cat
felin
infecti
periton
fip
therapeut
drug
effect
fip
yet
develop
peptid
base
viral
protein
amino
acid
sequenc
recent
attract
attent
new
antivir
drug
present
studi
synthes
overlap
peptid
base
amino
acid
sequenc
domain
type
fipv
strain
protein
investig
inhibitori
effect
fipv
infect
evalu
inhibitori
effect
type
fipv
infect
peptid
investig
method
increas
infect
effici
poorli
replic
type
fipv
effici
type
fipv
infect
increas
dilut
viru
medium
contain
polyc
peptid
significantli
decreas
infect
fipv
strain
exhibit
mark
inhibitori
effect
fipv
infect
inhibitori
effect
fipv
infect
peptid
type
type
ii
fipv
strain
felin
herpesviru
fhv
felin
caliciviru
fcv
also
examin
peptid
specif
inhibit
type
type
ii
fipv
fhv
fcv
infect
conclus
possibl
peptid
deriv
protein
type
fipv
strain
antifipv
agent
effect
type
also
type
ii
fipv
demonstr
vitro
felin
coronaviru
fcov
belong
alpha
coronavirus
famili
coronavirida
fcov
classifi
serotyp
ii
accord
spike
protein
properti
hohdatsu
et
al
motokawa
et
al
motokawa
et
al
type
consist
two
virus
felin
infecti
periton
fip
caus
fip
viru
fipv
nonfipcaus
felin
enter
coronaviru
fecv
pedersen
et
al
fipv
fecv
serotyp
distinguish
antigen
gene
level
differ
pathogen
cat
pedersen
cat
develop
fip
affect
sever
organ
includ
liver
lung
spleen
central
nervou
system
form
lesion
accompani
necrosi
pyogen
granulomat
inflamm
cat
pleural
effus
ascit
fluid
accumul
antifcov
antibodyposit
cat
inocul
fipv
onset
time
fip
earlier
antibodyneg
cat
symptom
sever
baldwin
scott
barlough
et
al
pedersen
pedersen
et
al
stoddart
et
al
weiss
scott
result
experi
studi
suggest
antibodydepend
enhanc
ade
fipv
infect
seriou
obstacl
prevent
fip
vaccin
fcov
protein
consid
class
fusion
protein
similarli
coronavirus
sever
acut
respiratori
syndromecoronaviru
mous
hepat
viru
transmiss
gastroenter
coronaviru
bosch
et
al
olsen
protein
exist
radial
protrud
trimer
viral
envelop
structur
function
divid
two
domain
name
domain
repres
ntermin
globular
head
ctermin
membranebound
stalk
respect
ctermin
domain
contain
receptorbind
domain
rbd
neutral
antibodybind
epitop
ade
epitop
corapi
et
al
hohdatsu
et
al
hohdatsu
et
al
hohdatsu
et
al
kida
et
al
olsen
et
al
ntermin
domain
sequenti
contain
put
fusion
peptid
respons
drive
viral
target
cell
membran
fusion
past
forti
year
sever
studi
investig
potenti
treatment
fip
hartmann
ritz
antivir
immunostimul
immunosuppress
drug
experiment
use
treatment
fip
http
elsevi
bv
right
reserv
exhibit
suffici
therapeut
effect
sever
agent
significantli
inhibit
fcov
replic
vitro
identifi
balzarini
et
al
barlough
shacklett
hsieh
et
al
kim
et
al
takano
et
al
takano
et
al
peptid
base
viral
protein
amino
acid
sequenc
recent
attract
attent
new
antivir
drug
peptid
bind
viral
protein
receptor
cell
inhibit
viral
infect
hiv
infectioninhibit
peptid
hivderiv
sequenc
current
use
human
medic
field
treat
patient
hiv
peptid
specif
bind
hiv
fusion
protein
block
cell
membran
fusion
induc
fusion
protein
furthermor
peptid
sequenc
deriv
rbd
japanes
enceph
viru
jev
specif
bind
viru
receptor
cell
competit
inhibit
jev
infect
clarifi
peptid
viral
proteinderiv
sequenc
inhibit
viral
infect
bind
viru
viru
receptor
li
et
al
li
et
al
liu
et
al
report
fipv
fusion
proteinderiv
peptid
exhibit
antivir
effect
although
fipv
rbdderiv
peptid
may
exhibit
antivir
activ
yet
investig
rbdderiv
peptid
antivir
activ
identifi
may
applic
antivir
agent
fipv
present
studi
synthes
overlap
peptid
base
amino
acid
sequenc
domain
type
fipv
strain
protein
presenc
rbd
expect
also
investig
inhibit
type
fipv
infect
peptid
use
plaqu
assay
inhibit
type
ii
fipv
infect
peptid
also
examin
thirti
differ
peptid
sequenc
deriv
domain
type
fipv
strain
tabl
synthes
sigmaaldrich
usa
peptid
synthes
fragment
overlap
peptid
dissolv
tabl
amino
acid
sequenc
peptid
deriv
domain
fipv
peptid
amino
acid
sequenc
start
posit
isoelectr
point
vtdfqpannsvshipfgkta
vshipfgktahfcfanfsh
hfcfanfshsivsrqflgil
ivsrqflgilpptvrefafg
pptvrefafgrdgsifvngi
rdgsifvngykyfslpair
kyfslpairsvnfsissve
vnfsissveeygfwtiaytn
ygfwtiaytnytdvmvdvng
ytdvmvdvngtaitrlfycd
taitrlfycdsplnrikcqq
splnrikcqqlkhelpdgfi
lkhelpdgfysasmlvkkdl
sasmlvkkdlpktfvtmpqf
pktfvtmpqfyhwmnvtlhv
yhwmnvtlhvvlndtekkyd
vlndtekkydiilakapela
iilakapelaaladvhfeia
aladvhfeiaqangsvtnvt
qangsvtnvtslcvqarqla
slcvqarqlalfykytslqg
lfykytslqglytysnlvel
lytysnlvelqnydcpfspq
qnydcpfspqqfnnylqfet
qfnnylqfetlcfdvnpava
lcfdvnpavagckwslvhdv
gckwslvhdvqwrtqfatit
qwrtqfatitvsykhgsmit
vsykhgsmitthakghswgf
thakghswgfqdtsvlvkd
dimethyl
sulfoxid
dmso
mm
aliquot
store
c
solvent
control
dmso
dilut
medium
use
method
prepar
peptid
stock
solut
feli
catu
whole
cell
crandel
felin
kidney
crfk
cell
atcc
swine
kidney
cpk
cell
grown
eagl
minimum
essenti
medium
contain
medium
fetal
calf
serum
fc
unitml
penicillin
mgml
streptomycin
cell
maintain
humidifi
co
incub
c
cell
suppli
dr
c
horzinek
state
univers
utrecht
netherland
cpk
cell
suppli
kitasato
institut
tokyo
japan
mab
mab
use
present
studi
mab
mab
develop
laboratori
respect
recogn
protein
protein
viru
demonstr
immunoblot
hohdatsu
et
al
c
type
fipv
strain
strain
black
strain
type
ii
fipv
strain
tgev
strain
ccov
strain
felin
herpesviru
fhv
strain
felin
caliciviru
fcv
strain
use
studi
fipv
strain
isol
laboratori
fipv
strain
black
suppli
dr
j
k
yamamoto
univers
florida
fipv
strain
suppli
dr
n
c
pedersen
univers
california
davi
fipv
strain
suppli
dr
c
horzinek
state
univers
utrecht
netherland
tgev
strain
suppli
nation
institut
anim
health
japan
fhv
strain
fcv
strain
suppli
dr
e
takahashi
univers
tokyo
japan
fipv
tgev
passag
cell
cpk
cell
respect
fhv
fcv
passag
crfk
cell
viru
passag
two
three
time
laboratori
use
subsequ
experi
strain
potenc
pfuml
use
experi
deaedextran
ge
healthcar
uk
ltd
england
polybren
sigmaaldrich
usa
protamin
sigmaaldrich
usa
use
polyc
dextran
sulfat
ge
healthcar
uk
ltd
england
heparin
ajinomoto
japan
use
polyanion
fipv
strain
dilut
medium
contain
polyc
polyanion
variou
concentr
cell
seed
plate
inocul
l
pfuml
viral
suspens
incub
c
min
incub
cell
wash
medium
ml
medium
contain
fc
carboxymethyl
cellulos
ad
well
cultur
incub
c
day
fix
buffer
formalin
stain
crystal
violet
peptid
stock
solut
dilut
medium
contain
fc
deaedextran
gml
l
solut
ad
cell
seed
plate
follow
incub
rt
min
cell
sensit
dmso
dilut
fold
peptid
stock
solut
solvent
control
cell
inocul
l
pfuml
viral
suspens
without
wash
incub
c
min
incub
cell
wash
medium
ml
medium
contain
fc
carboxymethyl
cellulos
ad
well
cultur
incub
c
day
fix
buffer
formalin
stain
crystal
violet
percent
plaqu
inhibit
calcul
follow
formula
plaqu
inhibit
plaqu
number
well
contain
viru
alon
plaqu
number
well
contain
peptid
dmso
plaqu
number
well
contain
viru
alon
investig
whether
chang
peptid
influenc
effect
polyc
plaqu
inhibit
test
perform
use
medium
contain
deaedextran
gml
investig
reaction
condit
need
peptid
exhibit
inhibitori
effect
fipv
infect
peptidetr
cell
wash
inocul
viru
cell
combin
dilut
peptid
solut
dmso
solvent
control
react
rt
min
cell
wash
combin
l
medium
contain
fc
deaedextran
follow
inocul
l
pfuml
viru
suspens
procedur
thereaft
describ
time
whether
peptid
exhibit
inhibitori
effect
fipv
infect
without
presensit
cell
investig
cell
combin
l
medium
contain
fc
deaedextran
kept
stand
rt
min
medium
remov
cell
inocul
mixtur
viru
peptid
dmso
mixtur
peptid
type
ii
fipv
strain
moi
ad
cell
react
c
h
mixtur
dmso
solvent
control
viru
ad
cell
control
cell
wash
three
time
icecold
medium
contain
nan
incub
mab
mab
c
min
amino
acid
sequenc
coronaviru
protein
refer
genbank
access
number
type
fipv
strain
strain
black
strain
type
ii
fipv
strain
align
comparison
amino
acid
sequenc
fulllength
protein
perform
use
clustalw
http
clustalwddbjnig
acjp
result
align
comparison
shown
fig
data
two
group
analyz
student
test
multipl
group
analyz
tukeykram
method
dunnett
test
tukeykram
method
use
investig
reaction
condit
need
peptid
exhibit
inhibitori
effect
fipv
infect
multipl
group
experi
analyz
use
dunnett
test
influenc
polyanion
polyc
type
fipv
infect
investig
polyanion
dextran
sulfat
heparin
ad
cultur
medium
infect
effici
fipv
strain
decreas
fig
contrast
polyc
deaedextran
polybren
protamin
ad
infect
effici
markedli
enhanc
polyc
concentr
increas
synthes
overlap
peptid
base
amino
acid
sequenc
domain
type
fipv
strain
protein
presenc
rbd
expect
inhibitori
effect
peptid
infect
homolog
strain
investig
use
plaqu
assay
base
polycationinduc
enhanc
infect
observ
mem
contain
gml
deaedextran
use
cell
ad
cultur
medium
use
dilut
type
fipv
strain
cell
inocul
viral
suspens
allow
h
viral
adsorpt
cell
wash
medium
contain
fc
carboxymethyl
cellulos
ad
well
cell
cultur
c
day
stain
crystal
violet
plaqu
format
rate
calcul
follow
equat
percentag
plaqu
number
plaqu
well
inocul
viral
suspens
dilut
polycationor
polyanioncontain
mediumnumb
plaqu
well
inocul
viral
suspens
dilut
medium
contain
polyc
polyanion
experi
perform
triplic
figur
show
mean
standard
error
seed
plate
combin
l
peptid
solut
dilut
react
rt
min
cell
inocul
l
l
viral
suspens
without
wash
peptid
test
significantli
inhibit
infect
fipv
strain
fig
dosedepend
manner
fig
c
isoelectr
point
peptid
inhibit
fipv
infect
acid
particularli
suggest
viral
infect
inhibit
reduct
effect
polyc
deaedextran
peptid
thu
chang
deaedextran
concentr
investig
infectioninhibitori
effect
peptid
fig
inhibit
viral
infect
regardless
deaedextran
concentr
contrast
inhibit
infect
concentr
deaedextran
although
isoelectr
point
low
reaction
condit
need
peptid
exhibit
inhibitori
effect
fipv
strain
infect
investig
cell
wash
reaction
peptid
inocul
viru
inhibitori
effect
significantli
decreas
fig
cell
simultan
react
peptid
viru
without
wash
number
plaqu
reduct
calcul
horizont
stripe
bar
black
bar
gray
bar
hatch
bar
dmso
experi
perform
triplic
figur
show
mean
standard
error
peptid
pretreat
peptid
inhibit
infect
higher
inhibitori
effect
equival
observ
cell
pretreat
peptid
inocul
viru
inhibit
infect
fipv
strain
fiv
fcv
use
exhibit
mark
inhibitori
effect
type
fipv
strain
infect
investig
significantli
inhibit
infect
type
fipv
strain
black
fig
also
significantli
inhibit
infect
type
ii
fipv
strain
inhibitori
effect
fipv
strain
infect
equival
fipv
strain
contrast
inhibitori
effect
infect
observ
fhv
strain
fcv
strain
peptid
determin
whether
peptid
examin
decreas
viral
adsorpt
effici
use
flow
cytometr
analysi
peptid
exhibit
potent
inhibitori
effect
fipv
infect
use
peak
present
fluoresc
intens
lin
histogram
cell
without
viral
adsorpt
viru
adsorb
cell
peak
fluoresc
intens
shift
fig
similarli
cell
inocul
mixtur
dmso
viru
peak
histogram
shift
fig
contrast
cell
inocul
mixtur
viru
peak
present
fig
ie
peak
inocul
mixtur
shift
left
greater
extent
inocul
viru
alon
virusdmso
mixtur
level
viral
adsorpt
cell
evalu
base
mean
fluoresc
intens
mfi
ie
rate
inhibit
viral
adsorpt
peptid
calcul
viral
adsorpt
level
significantli
lower
cell
inocul
mixtur
inocul
dmsoviru
mixtur
fig
synthes
overlap
peptid
base
amino
acid
sequenc
type
fipv
strain
protein
investig
inhibitori
effect
type
fipv
type
ii
fipv
infect
peptid
type
fipv
poorli
replic
cell
evalu
inhibitori
effect
type
fipv
infect
peptid
initi
investig
method
increas
infect
effici
type
fipv
accur
evalu
inhibitori
effect
type
fipv
infect
examin
addit
polyc
polyanion
dilut
viral
suspens
viral
suspens
dilut
medium
contain
polyc
subject
infect
cell
number
type
fipv
plaqu
increas
manner
depend
polyc
concentr
contrast
viral
suspens
dilut
polyanioncontain
medium
number
plaqu
decreas
manner
depend
polyanion
concentr
polycationinduc
increas
polyanioninduc
decreas
viral
infect
effici
report
virus
tgev
mhv
vesicular
stomat
viru
vsv
bailey
et
al
hirano
et
al
nguyen
et
al
bailey
et
al
demonstr
posit
charg
polyc
increas
electrostat
interact
viral
particl
cell
surfac
promot
bind
viral
particl
cell
similarli
polyc
may
enhanc
electrostat
interact
viru
cell
surfac
increas
type
fipv
infect
effici
overlap
peptid
synthes
significantli
decreas
type
fipv
strain
infect
rate
isoelectr
point
peptid
acid
suggest
peptid
reduc
effect
polyc
decreas
number
plaqu
howev
significantli
inhibit
type
fipv
strain
infect
regardless
polyc
concentr
moreov
show
infectioninhibitori
effect
although
isoelectr
point
low
base
find
infectioninhibitori
effect
exhibit
regardless
charg
peptid
addit
partial
overlap
amino
acid
sequenc
peptid
similar
inhibitori
effect
contrast
partial
overlap
partial
lap
show
inhibitori
effect
find
suggest
amino
acid
sequenc
import
exhibit
inhibitori
effect
fipv
infect
antivir
effect
peptid
type
ii
fipv
felin
herpesviru
felin
caliciviru
cell
incub
peptid
dmso
solvent
control
min
rt
cell
infect
type
fcov
strain
black
typeii
fcov
strain
fhv
strain
fcv
strain
respect
stain
reduct
number
plaqu
calcul
horizont
stripe
bar
black
bar
gray
bar
dmso
experi
perform
triplic
figur
show
mean
standard
error
present
studi
synthes
overlap
peptid
base
amino
acid
sequenc
domain
type
fipv
strain
protein
presenc
rbd
expect
basi
previou
report
domain
fipv
expect
involv
rbd
breslin
et
al
reguera
et
al
regan
et
al
li
et
al
report
jev
rbdderiv
peptid
inhibit
jev
infect
competit
block
bind
jev
cell
li
et
al
li
et
al
reguera
et
al
report
tgev
rbd
region
exhibit
inhibitori
effect
type
ii
fipv
infect
includ
tgev
rbd
inhibit
test
fipv
adsorpt
cell
viral
bind
cell
found
reduc
base
result
assum
least
competit
inhibit
viral
bind
cell
significantli
decreas
fipv
infect
effici
howev
inhibitori
effect
fipv
infect
markedli
decreas
cell
inocul
viru
presensit
peptid
wash
find
indic
peptid
interact
viru
protein
cellular
viru
receptor
howev
data
fig
could
explain
intern
peptidebound
receptor
replac
new
popul
via
membran
recycl
investig
beed
elucid
action
mechan
peptid
detail
exhibit
mark
inhibitori
effect
type
fipv
infect
experi
investig
inhibitori
effect
peptid
type
ii
fipv
strain
fhv
fcv
infect
significantli
inhibit
type
ii
fipv
infect
inhibit
infect
type
fipv
strain
effect
type
ii
fipv
infect
less
comparison
amino
acid
sequenc
protein
among
coronaviru
strain
amino
acid
sequenc
show
ident
similar
type
fipv
exclud
ident
similar
type
ii
fipv
fig
suggest
reduc
inhibitori
effect
type
ii
fipv
infect
attribut
reduc
amino
acid
sequenc
homolog
contrast
amino
acid
sequenc
well
conserv
type
ii
fipv
result
suggest
broad
antivir
activ
felin
coronaviru
regardless
serotyp
furthermor
similar
effect
type
type
ii
fipv
suggest
common
receptor
bind
site
two
virus
howev
previou
studi
show
type
type
ii
fipv
distinct
receptor
hohdatsu
et
al
b
reason
discrep
unknown
case
elucid
identif
viru
receptor
type
fipv
necessari
fipv
serolog
classifi
type
ii
type
induc
fip
cat
type
serolog
crossreact
pedersen
et
al
shiba
et
al
sinc
type
ii
fipv
activ
replic
cell
line
pathogen
cat
previou
studi
fipv
antifipv
agent
perform
use
type
ii
fipv
howev
studi
yet
conduct
search
effect
antivir
agent
type
fipv
sinc
mani
cat
infect
type
fipv
field
import
clinic
veterinarian
prepar
antifipv
agent
effect
type
fipv
addi
et
al
hohdatsu
et
al
kummrow
et
al
shiba
et
al
present
studi
identifi
peptid
exhibit
coronavirusspecif
infectioninhibitori
effect
show
mark
inhibitori
effect
type
fipv
strain
infect
suggest
peptid
also
effect
wild
strain
addit
show
mark
inhibitori
effect
type
also
type
ii
fipv
infect
suggest
practic
applic
antifipv
agent
blood
elimin
halflif
peptid
prepar
gener
short
modif
polyethylen
glycol
appli
prolong
halflif
alvarez
et
al
et
al
shechter
et
al
marastoni
et
al
report
intramolecular
circular
peptid
becam
resist
enzym
circul
brain
halflifeextend
method
fusion
peptid
albumin
immunoglobulin
fc
domain
also
report
sockoloski
et
al
yeh
et
al
zettlmeissl
et
al
applic
modif
method
need
investig
modifi
peptid
administ
cat
possibl
peptid
deriv
protein
type
fipv
strain
antifipv
agent
effect
type
also
type
ii
fipv
demonstr
vitro
investig
peptid
modif
method
vivo
effect
peptid
desir
